Adiponectin level
Related entities
Findings (27)
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99
None
improvementHigher baseline adiponectin was associated with lower risk of incident diabetes in the placebo group of the DPP, independent of traditional diabetes risk factors including BMI, fasting glucose, insuli
Effect: improvement; HR 0.84; CI: 95% CI 0.71, 0.99